The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.
Dr McArthur on Neoadjuvant Pembrolizumab Plus Chemotherapy in ER+/HER2– Breast Cancer
October 23rd 2023Heather Lynn McArthur, MD, MPH, discusses the primary results from the phase 3 KEYNOTE-756 study of neoadjuvant pembrolizumab plus chemotherapy in early-stage, high-risk, estrogen receptor–positive, HER2-negative breast cancer.
Watch
Dato-DXd Provides PFS Benefit in HR+/HER2– Breast Cancer
October 23rd 2023Datopotamab deruxtecan elicited a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy for patients with hormone receptor-positive, HER2-low or -negative, metastatic breast cancer.
Read More
Dr Esteva on the Impact of the MAINTAIN Trial in HR+/HER2– Breast Cancer
October 21st 2023Francisco J. Esteva, MD, PhD, discusses the impact of the phase 2 MAINTAIN study of treatment with ribociclib following progression on CDK4/6 inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.
Watch
Neoadjuvant Pembrolizumab Plus Chemotherapy Boosts pCR in ER+/HER2– Breast Cancer
October 20th 2023Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab plus endocrine therapy generated a statistically significant increase in pathologic complete response vs neoadjuvant placebo plus chemotherapy followed by adjuvant pembrolizumab and endocrine therapy in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.
Read More
Pembrolizumab Plus Neoadjuvant Chemotherapy Produces Long-Term Survival Benefits in High-Risk TNBC
October 20th 2023Treatment with neoadjuvant pembrolizumab in combination with platinum-containing chemotherapy and followed by adjuvant pembrolizumab improved event-free survival compared with neoadjuvant chemotherapy alone in patients with high-risk triple-negative breast cancer.
Read More
Adjuvant treatment with the combination of abemaciclib and endocrine therapy (ET) maintained a benefit in invasive disease-free survival and distant relapse–free survival compared with ET alone in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer.
Read More
The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC
October 20th 2023Jane Meisel, MD, elaborates on the evolution and significance of the antibody-drug conjugate trastuzumab deruxtecan in treating HER2+ metastatic breast cancer, highlighting its effectiveness and considerations for its usage.
Watch
Toxicity Management for T-DM1 and T-DXd in Breast Cancer
Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].
Watch
Antibody-Drug Conjugates in Breast Cancer
A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.
Watch
ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types
October 19th 2023The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.
Read More
Emerging Therapies Underscore Need for Genomic Testing in HR+/HER2– Breast Cancer
October 16th 2023Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.
Read More
Best Practices for Patient Education Surrounding Cancer Treatment
The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.
Watch
Molecular Testing Considerations in Cancer Treatment
Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.
Watch
Evolution of Advanced HER2+ Breast Cancer Management
October 13th 2023Jane Meisel, MD, highlights how recent advancements in HER2+ advanced breast cancer treatments such as the introduction of tucatinib and trastuzumab deruxtecan are transforming patient care, particularly for those with brain metastases.
Watch
Dr Krill-Jackson on the Practice-Changing Effect of T-DXd in HER2+ Breast Cancer
October 12th 2023Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.
Watch
Let’s Talk About Post-Mastectomy Chest Numbness
October 11th 2023Just as advances in surgical techniques have made it possible to treat breast cancer and offer numerous options for breast reconstruction, there is also a surgical advancement to address a functional impairment often unintentionally caused by mastectomy: chest numbness.
Read More
Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis
October 9th 2023Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.
Watch
Biomarker Testing in Gastrointestinal and Lung Cancers
Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.
Watch
Molecular Testing in Breast Cancer
A breast medical oncologist and nurse practitioner review molecular testing practices for patients with breast cancer.
Watch
SABR to Oligoprogressive Lesions Delays Systemic Therapy Change in ER+ Advanced Breast Cancer
October 5th 2023Administration of stereotactic ablative body radiotherapy to oligoprogressive lesions delayed a change in systemic therapy in patients with estrogen receptor–positive/HER2-negative breast cancer enrolled to the prospective phase 2 AVATAR trial.
Read More